WRF
MBII

Waddell & Reed Financial’s Marrone Bio Innovations, Inc. MBII Stock Holding History

Waddell & Reed Financial’s Portfolio MBII Stock Details MBII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$49M Sell
23,445,757
-3,130,926
-12% -$6.5M 0.1% 234
2020
Q4 		$33.2M Buy
26,576,683
+1,481,049
+6% +$1.77M 0.07% 299
2020
Q3 		$30.6M Buy
25,095,634
+308,552
+1% +$375K 0.07% 284
2020
Q2 		$29M Buy
24,787,082
+385,690
+2% +$357K 0.08% 273
2020
Q1 		$19.9M Hold
24,401,392
– – 0.06% 285
2019
Q4 		$24.6M Sell
24,401,392
-313,500
-1% -$380K 0.06% 311
2019
Q3 		$34.8M Hold
24,714,892
– – 0.09% 242
2019
Q2 		$37.1M Hold
24,714,892
– – 0.09% 244
2019
Q1 		$37.8M Hold
24,714,892
– – 0.09% 260
2018
Q4 		$36.3M Hold
24,714,892
– – 0.1% 241
2018
Q3 		$45.2M Buy
24,714,892
+20,000,000
+424% +$38.8M 0.1% 235
2018
Q2 		$8.57M Sell
4,714,892
-20,000,000
-81% -$37.2M 0.02% 444
2018
Q1 		$47.3M Buy
24,714,892
+20,000,000
+424% +$26.8M 0.11% 219
2017
Q4 		$5.19M Hold
4,714,892
– – 0.01% 472
2017
Q3 		$5.42M Hold
4,714,892
– – 0.01% 465
2017
Q2 		$6.08M Hold
4,714,892
– – 0.01% 471
2017
Q1 		$9.19M Sell
4,714,892
-11,300
-0.2% -$23.9K 0.02% 431
2016
Q4 		$10.1M Sell
4,726,192
-41,900
-0.9% -$87.4K 0.02% 406
2016
Q3 		$8.2M Hold
4,768,092
– – 0.02% 435
2016
Q2 		$3.91M Hold
4,768,092
– – 0.01% 519
2016
Q1 		$4.29M Hold
4,768,092
– – 0.01% 503
2015
Q4 		$5.25M Hold
4,768,092
– – 0.01% 483
2015
Q3 		$10.1M Hold
4,768,092
– – 0.02% 401
2015
Q2 		$9.44M Hold
4,768,092
– – 0.01% 440
2015
Q1 		$18.5M Hold
4,768,092
– – 0.03% 353
2014
Q4 		$17.2M Hold
4,768,092
– – 0.02% 343
2014
Q3 		$12.7M Buy
4,768,092
+11,300
+0.2% +$75.5K 0.02% 378
2014
Q2 		$55.3M Buy
4,756,792
+2,984,892
+168% +$33.8M 0.08% 230
2014
Q1 		$24.8M Buy
1,771,900
+742,900
+72% +$11.7M 0.04% 313
2013
Q4 		$18.3M Buy
1,029,000
+29,000
+3% +$471K 0.03% 340
2013
Q3 		$16.9M Buy
+1,000,000
New +$14M 0.03% 340

Other funds holding MBII

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Waddell & Reed Financial's MBII Position: Q1 2021 in Review

Waddell & Reed Financial reduced its Marrone Bio Innovations, Inc. (MBII) stake by 12% in Q1 2021, selling an estimated $6.5M and leaving 23,445,757 shares worth $49M. The position accounts for 0.1% of the portfolio, ranked #234.

Waddell & Reed Financial first reported a position in MBII in Q3 2013 and has held it in 31 quarters since. The position peaked at $55.3M in Q2 2014. 74 funds tracked by Wall St. Rank hold MBII as of Q1 2021.

  • Waddell & Reed Financial held 23,445,757 shares of Marrone Bio Innovations, Inc. worth $49M as of Q1 2021.
  • Waddell & Reed Financial sold 3,130,926 Marrone Bio Innovations, Inc. shares in Q1 2021, an estimated $6.5M.
  • Marrone Bio Innovations, Inc. made up 0.1% of Waddell & Reed Financial's portfolio in Q1 2021, its #234 holding.
  • Waddell & Reed Financial first reported a position in Marrone Bio Innovations, Inc. in Q3 2013 and has held it in 31 quarters since.
  • Waddell & Reed Financial's Marrone Bio Innovations, Inc. position peaked at $55.3M in Q2 2014.
  • 74 funds tracked by Wall St. Rank held Marrone Bio Innovations, Inc. as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.